Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.63 |
| ▸ | NOS1 | P29475 | 2/20 | 0.63 |
| ▸ | NOS2 | P35228 | 2/20 | 0.63 |
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
| ▸ | GABRE | P78334 | 1/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744814 | 0.98 | NOS3 (0.61) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL8527159 | 0.98 | NOS3 (0.61) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL19309208 | 0.98 | NOS3 (0.61) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL5749578 | 0.98 | NOS3 (0.61) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL3443609 | 0.98 | NOS3 (0.61) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL11553700 | 0.98 | NOS3 (0.61) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL27678823 | 0.98 | NOS3 (0.61) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL5746040 | 0.98 | NOS3 (0.61) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL6938337 | 0.94 | NOS2 (0.66) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL105611 | 0.86 | NOS2 (0.70) | NOS3NOS1NOS2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040483-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2013-01-24 | — | — | US | claimed |
| JP-2011524416-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-2306985-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | Biovascular, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2010005480-A9 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| WO-2010005480-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-01-14 | — | — | WO | claimed |
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | BIOVASCULAR, INC. | 2009-12-31 | — | — | US | claimed |
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-9750698-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9700521-B2 | Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170112767-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2017-04-27 | — | — | US | disclosed |
| EP-3136461-A1 | PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL IN WHICH SAME IS USED, AND METHOD FOR MANUFACTURING PHOTOELECTRIC CONVERSION ELEMENT | Fujifilm Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9381198-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| CN-100484939-C | Polymorph forms of N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl) acetamide | MITSUBISHI PHARMACEUTICAL CORP (JP) | 2009-05-06 | — | — | CN | disclosed |
| EP-1979329-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089768-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EXELIXIS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| CN-1498219-A | Polymorphic forms of N- (2, 3-dimethyl-5, 6,7, 8-tetrahydrofuro [2, 3-b ] quinolin-4-yl) -2- (2-oxopyrrolidin-1-yl) acetamide | ������ҩ��ʽ���� | 2004-05-19 | — | — | CN | disclosed |
| US-4115397-A | 1,3,5,7-TETRA(2-PYRIDYLIMINO)-BENZODIPYRROLES | FORD MOTOR COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-3965100-A | 2,3-Dihydrocyclopenta[d]pyrido[1,2-a]pyrimidin-10(1H)-one and its derivatives | E. R. SQUIBB & SONS, INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | PF4, PLAT, VASP | NOS3 197/4885NOS1 384/4885NOS2 652/4885 |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | NOS3 399/4885NOS1 374/4885NOS2 872/4885 |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | NOS3 2237/4885NOS1 2664/4885NOS2 1297/4885 |
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | NOS3 399/4885NOS1 374/4885NOS2 872/4885 |
| US-20170112767-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | NOS3 399/4885NOS1 374/4885NOS2 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.